1-866-598-7166

Comparing One-Session vs. Multi-Session Radiation for Brain Metastases

Trial ID: NCT06500455
Kidney Cancer Type: Any


Background:

When cancer spreads to the brain, radiation therapy is often used to treat the tumors. Radiation uses high-energy X-rays to damage cancer cells so they stop growing or shrink over time.

Stereotactic radiosurgery (SRS) is a highly focused form of radiation therapy. Despite the name, it is not surgery. It delivers a single, strong dose of radiation directly to the brain tumor while limiting damage to nearby healthy brain tissue.

Fractionated stereotactic radiosurgery (FSRS) uses the same precise targeting but splits the radiation into several smaller treatments, usually over three sessions. Giving radiation over multiple treatments may help protect healthy brain tissue and reduce side effects.

 

The Trial:

In this study, patients are placed into one of two treatment groups by chance. Both treatments are not surgery and do not involve any incisions.

  • Stereotactic radiosurgery (SRS): a single session of highly focused radiation to the brain tumor over about 30–90 minutes. 
  • Fractionated stereotactic radiosurgery (FSRS): same type of focused radiation but spread over three treatment sessions

All patients will have CT and MRI scans to help plan the treatment and monitor how well it is working. 

The trial is not “blind”, so both you and your doctor will know which therapy you are receiving. 

 

Basic Eligibility:

  • 18 years or older
  • kidney cancer that has spread to the brain
  • You have between 1 and 8 brain tumors, seen on a recent MRI scan
  • At least one brain tumor is between 1 and 3 cm in size

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreThe Research Institute of the McGill University Health Centre (MUHC) Principal InvestigatorChristina Tsien LocationMontreal, QC Trial StatusRecruiting
Kidney Cancer Canada